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ABSTRACT
Introduction After primary infection, human 
herpesviruses establish latency and persist lifelong. 
Periodic virus reactivation can lead to serious inflammatory 
complications. Recent research suggests that herpesvirus 
reactivation may also be linked to acute stroke. An 
improved understanding of this relationship is vital to 
inform public health prevention strategies. We will review 
the evidence regarding the role of human herpesviruses in 
triggering stroke.
Methods and analysis A systematic literature review 
of published and grey literature studies with a human 
herpesvirus (infection or reactivation) as an exposure and 
stroke as an outcome will be carried out. Randomised 
controlled trials, cohort, case–control, case crossover 
and self-controlled case series designs will be eligible; 
no restrictions will be placed on publication status, 
language and geographical or healthcare setting. The 
Cochrane Central Register of Controlled Trials, Embase, 
Global Health, Medline, Scopus and Web of Science will 
be searched from dates of inception to January 2017. A 
prespecified search strategy of medical subject headings 
and free text terms (in the title and abstract) for human 
herpesviruses AND stroke will be used. Two reviewers 
will independently screen titles and abstracts for eligible 
studies, followed by full-text screening. The reviewers 
will then extract data from the eligible studies using 
standardised, pilot-tested tables and assess risk of bias in 
individual studies, in line with the Cochrane Collaboration 
approach. The data will be synthesised in a narrative 
format, and meta-analyses considered where there are 
sufficient data. Quality of evidence will be assessed in 
line with theGrading of Recommendations, Assessment, 
Development and Evaluation (GRADE) approach.
Ethics and dissemination As this is a systematic 
review, ethical approval is not required. The results will 
be submitted for peer-review publication and presented 
at national conferences. A lay and short summary will be 
disseminated on appropriate webpages.
PROSPERO registration number CRD42017054502
IntroductIon
rationale
Stroke is the world’s second most common 
cause of death1 and the leading cause of 
complex disability in the UK.2 Age is the most 
important risk factor for stroke.2 Although 
the incidence of stroke is falling, the ageing 
population means that the burden of disease 
due to stroke (including disability, illness 
and premature death) is projected to double 
worldwide by 2030.1 While traditional risk 
factors for stroke are well characterised,3 
a growing literature highlights the role of 
non-traditional transient factors such as infec-
tions as vascular triggers.4
The herpesviruses are a family of common 
persistent viruses that may reactivate peri-
odically from latency to cause substantial 
morbidity through inducing a range of 
inflammatory effects. Reactivation of varicella 
zoster virus (VZV) causes an acute shingles 
(or herpes zoster) episode, resulting in tissue 
damage and inflammation, and reactivation 
of herpes simplex virus types 1 and 2 can lead 
to corneal blindness and meningoencepha-
litis.5
Recent population studies have shown a 
short-term increase in the risk of stroke in 
months following infection with or reac-
tivation of VZV.6–8 These data come from 
powerful self-controlled case series studies 
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Protocol
Strengths and limitations of this study
 ► This systematic review will comprehensively 
evaluate studies of both infection with, and 
reactivation of, all eight human herpesviruses and 
the risk of subsequent stroke.
 ► An improved understanding of this relationship 
may help to inform public health stroke prevention 
strategies.
 ► We will use the GRADE (Grading of Recommendations, 
Assessment, Development and Evaluation)  system 
to ascertain the strength of the evidence base for 
each human herpesvirus and the risk of stroke, and 
report data in a ‘Summary of Findings’ table.
 ► Included studies may have substantially different 
methodologies, which could limit our ability to draw 
reliable conclusions from the existing evidence base.
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using primary care electronic health records from 
both the UK and USA, and are corroborated by several 
prospective cohort studies using data from Asian and 
European populations.9–12 The effects of other members 
of the herpesvirus family on vascular events are less clear, 
although cytomegalovirus (CMV) is hypothesised to 
modulate stroke risk, especially among immunocompro-
mised populations.13
Two recently published reviews investigated the 
evidence for short and long-term risks of stroke after 
herpes zoster.14 15 One showed a risk ratio of 1.36 (95% 
CI 1.10 to 1.67) for the association between herpes 
zoster and stroke pooled across six cohort studies.15 The 
other meta-analysis used data from eight studies to show 
a gradient of stroke risk decreasing from 2.36 (95% CI 
2.17 to 2.56) in the first 2 weeks after herpes zoster to 
1.56 (95% CI 1.46 to 1.66) at 1 month, 1.17 (95% CI 
1.13 to 1.22) at 1 year and 1.09 (95% CI 1.02 to 1.16) 
after 1 year.14 These studies were limited to clinical VZV 
reactivation, and did not investigate risks associated with 
initial infection, or subclinical reactivation. Although 
one of the reviews presented results for some subgroup 
analyses,15 the exclusion of self-controlled case series 
studies limited power to detect effects on population 
subgroups or stroke subtypes.
To extend the work carried out in previous reviews, we 
will comprehensively review studies of both infection with 
and reactivation of all eight human herpesviruses and 
risk of stroke. In prespecified subgroup analyses, we will 
assess whether the effects of herpesviruses on stroke differ 
among population subgroups, for example, stratified by 
age group and immune status, at different time periods 
after infection or reactivation and on stroke subtypes. We 
will also assess whether there is any evidence that stroke 
risk is modulated by preventing or treating herpesvirus 
infection or reactivation using vaccines or antiviral agents 
such as acyclovir.
objectives
The primary objective of the planned systematic review is 
to investigate whether patients with primary infection, or 
reactivation of, human herpesviruses are at increased risk 
of stroke, compared with those without (or with latent) 
human herpesviruses.
The review will also assess the following secondary 
research questions:
1. Does preventing or treating human herpesviruses 
attenuate the risk of stroke?
2. Does the association between human herpesviruses 
and stroke vary by population characteristics (such 
as age and other common vascular risk factors)?
3. Does primary infection with or reactivation of 
human herpesviruses increase the risk of subtypes 
of stroke or transient ischaemic attack (TIA)?
These objectives will be addressed through a compre-
hensive review targeting all analytical epidemiological 
studies in humans of any age.
Methods
This protocol follows the Preferred Reporting Items for 
Systematic Reviews and Meta Analyses Protocols.16
eligibility criteria
Study designs and characteristics
We will include studies using randomised controlled 
trials, cohort, case–control, case crossover and self-con-
trolled case series designs, reporting an effect estimate 
or the data that allow its calculation. We will exclude 
cross-sectional studies, ecological studies, case series, 
case reports and reviews; however, relevant reviews will be 
flagged during the screening process and their references 
lists searched for potentially eligible studies. Studies from 
any time period, of any publication status, reported in any 
language and conducted in any geographical and health-
care setting (including inpatient, outpatient, primary 
care and community settings) will be considered.
Participants
Eligible studies will include human participants. Animal 
studies will not be included. No restrictions will be placed 
on studies according to the age and immunosuppression 
status of the participants.
Exposure
The exposures of interest are infection with or reactivation 
(first or subsequent) of the eight human herpesviruses: 
specifically, herpes simplex virus types 1 and 2, VZV, 
Epstein-Barr virus, CMV, human herpesvirus 6, human 
herpesvirus 7 and human herpesvirus 8. Studies involving 
an exposed participant group whose members self-report 
infection or reactivation with a human herpesvirus, or 
who have a confirmed diagnosis, either through clinical 
or laboratory criteria, will be included in the review. We 
will also include vaccination against herpesviruses (eg, 
zostavax vaccine) and treatment for herpesviruses (eg, 
antivirals such as acyclovir) in order to investigate whether 
preventing or treating human herpesviruses attenuates 
the risk of stroke (a secondary research question).
Comparators
 Eligible studies must include a comparator group who are 
unexposed, that is, people (or person time for self-con-
trolled case series designs) without herpesvirus infections 
or with latent herpesvirus infections.
Outcomes
Studies will be included in the review if the primary 
outcome was any stroke, clinically diagnosed or self-re-
ported, and the patient’s first ever or subsequent stroke. 
For studies meeting the inclusion criteria, we will addi-
tionally assess the following secondary outcomes: TIA 
(a transient episode of neurological dysfunction caused 
by focal brain, spinal cord or retinal ischaemia without 
acute infarction)17 and subtypes of stroke (ischaemic 
vs haemorrhagic). Most strokes (approximately 85%)2 
are ischaemic (an episode of neurological dysfunction 
caused by focal, cerebral, spinal or retinal infarction),17 
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compared with haemorrhagic (neurological dysfunction 
caused by a focal collection of blood within or on the 
surface of the brain).17
Eligibility criteria may be further developed, in an iter-
ative process, after preliminary searches.
Information sources
The following databases will be searched for relevant arti-
cles, from dates of inception to January 2017; Cochrane 
Central Register of Controlled Trials (The Cochrane 
Library), Embase, Global Health, Medline, Scopus and 
Web of Science. Additional sources which will be searched 
include clinical trials registers (such as  ClinicalTrials. gov) 
and grey literature including the New York Academy of 
Medicine Grey Literature Report (www. greylit. org) and 
the Electronic Theses Online Service through the British 
Library (http:// ethos. bl. uk). PROSPERO will also be 
periodically checked for ongoing and completed system-
atic reviews concerning stroke and herpesviruses.
search strategy
The search strategy will consist of searching medical 
subject heading terms and free text (in the title and 
abstract) for the concepts ‘human herpesviruses’ and 
‘stroke’ (combined with the Boolean logic operator AND). 
The provisional search terms have been developed for the 
database MEDLINE and will be transcribed into appro-
priate search terms for the other information sources. 
The list of proposed search terms has been reviewed by all 
collaborators, including those with medical knowledge of 
the subject area, and necessary adjustments were made. 
The provisional search terms for MEDLINE are listed in 
the  online supplementary appendix.
We will review the reference lists of eligible articles and 
relevant reviews to identify additional papers not indexed 
in the databases searched.
study records
Data management
 Citations identified from the literature search will be 
downloaded into EndNote V. X7.5 and duplicate records 
removed by one author.
Selection process
 Two researchers (HF and CWG) will review all titles and 
abstracts in parallel to select studies for inclusion. To 
reduce the risk of missing potentially relevant studies, a 
deliberately lenient approach will be adopted for this first 
level of screening. Both authors will then obtain full-text 
articles for studies deemed to potentially meet the review 
criteria. Reasons for rejection of articles during the 
full-text screening process will be noted, according to a 
hierarchical list (ineligible study design, wrong exposure, 
wrong outcome, insufficient information to calculate 
an effect estimate). Any discrepancies will be discussed 
by HF and CWG and consultation with a third reviewer 
(CM) will be carried out where necessary.
Data extraction 
Information will be extracted from each study selected 
for review. Data extraction tables will be piloted by two 
authors (HF and CWG) for three studies and changes to 
the extraction tables made as required. Any discrepancies 
between the two authors will be discussed, and consul-
tation with a third author (CM) carried out if required. 
Data will be extracted for each remaining study by a single 
author (HF). Consideration will be given to contacting 
corresponding authors for any missing information or 
clarification on unclear information, using a standard 
email template.
data items
Data will be extracted using a standardised template. We 
will use the PICOS18 (Population, Intervention, Compar-
ator, Outcomes and Study design) framework, originally 
devised to formulate a research question, as a basis to 
develop data extraction criteria. As this is an aetiological 
study, ‘exposure’ will replace ‘intervention’ and ‘study 
characteristics’ will replace ‘study design’. Data items on 
the following five domains will be extracted:
1. Population: characteristics of the study population 
(eg, mean/median age, ethnic distribution, 
immune status), inclusion and exclusion criteria
2. Exposure: definition and identification of human 
herpesvirus exposure, number of exposed subjects
3. Comparators: definition and identification of 
unexposed individuals, number of unexposed 
subjects
4. Outcomes: definition and identification of primary 
(stroke) and secondary outcomes (stroke subtypes 
or TIA), number of subjects with outcome
5. Study characteristics: authors, publication year, 
setting/source of participants, design, methods of 
recruitment and sampling, period of study, length 
of follow-up time (if relevant), aims and objectives.
In terms of the study results, unadjusted and fully 
adjusted effect estimates for the association between 
herpesviruses and stroke will be recorded. Details of 
the confounders measured and adjusted for will also be 
noted. Results of any additional stratified analyses will 
also be recorded. Where possible, results from additional 
subgroup analyses with evidence regarding our non-pri-
mary objectives will also be recorded, for example, the 
association between herpesviruses and the secondary 
outcomes (stroke subtype or TIA).
outcomes and prioritisation
The primary clinical outcome of interest is the first record 
of stroke following infection with or reactivation of a 
human herpesvirus. Where studies report several results 
for risk of stroke following herpesvirus exposure we will 
prioritise, stroke diagnosed objectively (eg, through 
neuroimaging) or clinically, for example, meeting the 
American Heart Association/American Stroke Associa-
tion definition,17 outcomes reported for the whole cohort 
(rather than subsets of the cohort, whose association 
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between the herpesvirus and stroke may differ) and fully 
adjusted estimates of effect (rather than crude estimates). 
We will also extract data on the following secondary 
outcomes, where they are reported: TIA and subtypes of 
stroke (ie, ischaemic vs haemorrhagic). Data extraction 
for these additional outcomes will be prioritised in the 
same way as the primary outcome. Studies in which expo-
sures were recorded prior to outcomes will be prioritised 
when considering the overall quality of included studies.
risk of bias in individual studies
Two authors (HF and CWG) will independently evaluate 
the risk of bias in three studies, and any discrepancies will 
be discussed and our third reviewer (CM) consulted if 
necessary. HF will then carry out the risk of bias assess-
ment for the remaining studies. We will consider a series 
of relevant areas of bias (or domains) for each indi-
vidual study, in line with the Cochrane Collaborations 
risk of bias approach.19–21 For observational studies, 
domains will include bias due to (1) confounding; (2) 
selection of participants; (3) differential and non-differ-
ential misclassification of variables (exposures, outcomes 
and covariates); and (4) bias due to missing data. For 
randomised controlled trials, domains will include 
random sequence generation, allocation concealment, 
blinding, completeness of outcome data and selective 
reporting. Each domain will be classified as either ‘high 
risk’ (if criterion are inadequately addressed), ‘low risk’ 
(if criterion are adequately addressed) or ‘unclear risk’ (if 
information is insufficient to formulate a judgement). A 
summary risk of bias table will be produced, with an addi-
tional table briefly justifying each judgement included in 
the appendix.
data synthesis and meta-bias(es)
We will use a narrative synthesis, in which studies are 
grouped by each specific herpesvirus exposure, to 
summarise the evidence for the association between the 
herpesvirus and our primary outcome (stroke). If there 
are sufficient data in the selected studies, our narrative 
synthesis will also describe subgroup analyses, relevant to 
our secondary research questions. These include (1) the 
effect of herpesviruses on stroke, according to whether 
patients were vaccinated (eg, with the chickenpox vaccine 
or the herpes zoster vaccine) or received antiviral treat-
ment against herpesviruses; (2) the effect of herpesviruses 
on stroke for population characteristics, such as age strata 
and other common vascular risk factors; and (3) the effect 
of herpesviruses on the secondary outcomes TIA and 
stroke subtype (such as ischaemic stroke or haemorrhagic 
stroke, timing of stroke, first or subsequent stroke).
If there are at least two eligible studies assessing the 
same herpesvirus as a risk factor for our primary (stroke) 
or secondary (TIA or stroke type) outcomes, which are 
sufficiently homogeneous in terms of design, study 
population and outcome, we will consider conducting a 
meta-analysis to calculate a pooled effect estimate. The 
choice of whether to conduct a meta-analysis and which 
model to adopt (fixed or random effects) will be guided 
by the level of statistical heterogeneity assessed using the 
Cochrane Q statistic and the I² statistic. An I²>50% will be 
used as a threshold to indicate moderate heterogeneity 
and potential to use of a random effects model, if there 
is overall consistency in the direction of effect. We will 
investigate sources of heterogeneity by removing studies 
at high risk of bias and comparing summary estimates 
from different study-level methodological and clinical 
characteristics (such as stroke definition, study design 
and age of the study population), using meta-regression 
where appropriate. Publication bias will be considered 
using funnel plots. All of the statistical analyses will be 
performed using STATA V. 14.0.
confidence in cumulative evidence
The Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE)22 approach will be used 
to summarise the quality of cumulative evidence for each 
herpesvirus on our outcomes, stratified by exposure defi-
nition and population characteristics. In addition to the 
risk of bias domains outlined earlier, we will also assess 
inconsistency between studies, indirectness, imprecision 
of estimates and publication bias (using a funnel plot) 
as outlined in the GRADE approach.23 The strength of 
evidence will be categorised as ‘high’, ‘moderate’ or ‘low/
very low’, with observational studies starting as low-quality 
evidence, but upgraded to moderate or even high quality 
in the presence of factors that increase confidence in the 
estimated effect data (eg, having a large magnitude of 
effect, evidence of a dose response). These judgements 
will be presented in a ‘Summary of Findings’ table.
ethIcs and dIsseMInatIon
Important protocol amendments will be documented with 
a justification for deviating from the original protocol, 
and summarised in a protocol addendum and in the final 
published review.
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